Ventripoint's AI-Powered Cardiac Imaging System Submitted for Expedited Approval in China
Ventripoint Diagnostics announced that its VMS+ 4.0 system has been submitted for regulatory approval in China via an expedited 'green channel' pathway, potentially accelerating access to AI-driven cardiac diagnostics in a market with 330 million cardiovascular patients.
Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the company's VMS+™ 4.0 system to China's National Medical Products Administration (NMPA) for regulatory approval. The submission benefits from the NMPA's “green channel” pathway, an expedited review process for innovative medical technologies addressing significant clinical needs, which is expected to streamline the regulatory timeline and facilitate faster market access.
This milestone marks a key step in Ventripoint's global expansion strategy, particularly in China, which represents one of the world's largest and fastest-growing healthcare markets. Cardiovascular disease is the leading cause of mortality in China, affecting an estimated 330 million patients. Echocardiography is the most widely used cardiac imaging modality in the country due to its cost-effectiveness and portability, but variability in interpretation and limited access to advanced modalities like MRI have created demand for AI-driven tools that improve diagnostic accuracy.
Ventripoint's VMS+™ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by the company's proprietary Knowledge Based Reconstruction technology, the platform enables accurate assessment of all four heart chambers, aiding in the diagnosis and management of conditions such as congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA's green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption. China's scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology.”
Hugh MacNaught, President and CEO of Ventripoint Diagnostics, added: “Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy. China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, VMS+ has the potential to significantly expand access to high-quality cardiac care.”
The expedited green channel pathway is expected to reduce the time to market, offering a competitive advantage in a country where demand for advanced cardiac diagnostics is surging. Ventripoint's VMS+ system is already approved in the U.S., Europe, and Canada, and this submission represents a pivotal move into the Asian market. The company will provide further updates as the regulatory review progresses.